See‐Chun Phan

581 total citations
17 papers, 435 citations indexed

About

See‐Chun Phan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, See‐Chun Phan has authored 17 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in See‐Chun Phan's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Genomics and Diagnostics (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). See‐Chun Phan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer Genomics and Diagnostics (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). See‐Chun Phan collaborates with scholars based in United States, United Kingdom and Switzerland. See‐Chun Phan's co-authors include Stephen P. Hack, David S. Shames, David Cunningham, Manish A. Shah, Josep Tabernero, Meng Chen, Florian Lordick, Yung‐Jue Bang, Katja Schulze and Karen L. Reckamp and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

See‐Chun Phan

17 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
See‐Chun Phan United States 11 303 249 89 69 66 17 435
Anghel Adrian Udrea United States 8 261 0.9× 227 0.9× 96 1.1× 41 0.6× 96 1.5× 15 392
Elisa Tassinari Italy 8 217 0.7× 205 0.8× 145 1.6× 35 0.5× 84 1.3× 34 457
C. Ligorio Italy 5 401 1.3× 337 1.4× 139 1.6× 97 1.4× 85 1.3× 6 550
B. Killing Germany 7 288 1.0× 141 0.6× 40 0.4× 48 0.7× 57 0.9× 9 329
Keiichi Akahoshi Japan 12 216 0.7× 101 0.4× 139 1.6× 70 1.0× 99 1.5× 49 445
Rita P. Dalal United States 10 415 1.4× 311 1.2× 92 1.0× 95 1.4× 144 2.2× 21 622
Quanren Wang China 11 314 1.0× 169 0.7× 77 0.9× 32 0.5× 103 1.6× 25 440
Ayako Mizota Japan 9 387 1.3× 260 1.0× 111 1.2× 45 0.7× 173 2.6× 16 589
Minhao Fan China 6 305 1.0× 268 1.1× 175 2.0× 27 0.4× 40 0.6× 11 531

Countries citing papers authored by See‐Chun Phan

Since Specialization
Citations

This map shows the geographic impact of See‐Chun Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by See‐Chun Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites See‐Chun Phan more than expected).

Fields of papers citing papers by See‐Chun Phan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by See‐Chun Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by See‐Chun Phan. The network helps show where See‐Chun Phan may publish in the future.

Co-authorship network of co-authors of See‐Chun Phan

This figure shows the co-authorship network connecting the top 25 collaborators of See‐Chun Phan. A scholar is included among the top collaborators of See‐Chun Phan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with See‐Chun Phan. See‐Chun Phan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sathe, Abhishek G., et al.. (2024). Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer. Clinical Pharmacology & Therapeutics. 117(2). 570–578. 5 indexed citations
2.
Kwiatkowski, David J., Valerie W. Rusch, Jamie E. Chaft, et al.. (2019). Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).. Journal of Clinical Oncology. 37(15_suppl). 8503–8503. 106 indexed citations
3.
Velcheti, Vamsidhar, Edward S. Kim, Tarek Mekhail, et al.. (2018). Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.. Journal of Clinical Oncology. 36(15_suppl). 12001–12001. 34 indexed citations
4.
Rusch, Valerie W., Jamie E. Chaft, Bruce E. Johnson, et al.. (2018). Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).. Journal of Clinical Oncology. 36(15_suppl). 8541–8541. 40 indexed citations
5.
Lin, Steven H., Yan Lin, Daniel R. Gomez, et al.. (2017). DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).. Journal of Clinical Oncology. 35(15_suppl). 3064–3064. 12 indexed citations
6.
Bendell, Johanna C., Howard S. Höchster, Lowell L. Hart, et al.. (2017). A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist. 22(3). 264–271. 46 indexed citations
7.
Morley, Roland, Peter G. Hawkins, Y. Suzuki, et al.. (2015). Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program. PLoS ONE. 10(10). e0139679–e0139679. 18 indexed citations
8.
Bendell, Johanna C., Howard S. Höchster, Lowell L. Hart, et al.. (2015). A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 663–663. 6 indexed citations
9.
Shah, Manish A., Yung‐Jue Bang, Florian Lordick, et al.. (2015). METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. Journal of Clinical Oncology. 33(15_suppl). 4012–4012. 82 indexed citations
10.
Cunningham, David, Manish A. Shah, Dustin Smith, et al.. (2015). False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.. Journal of Clinical Oncology. 33(3_suppl). 16–16. 12 indexed citations
11.
12.
Lin, Thomas S., Louie Naumovski, Philip Lecane, et al.. (2009). Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 50(12). 1977–1982. 16 indexed citations
13.
Miles, Dale, Jennifer A. Smith, See‐Chun Phan, et al.. (2005). Population Pharmacokinetics of Motexafin Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme. The Journal of Clinical Pharmacology. 45(3). 299–312. 10 indexed citations
14.
Kahl, Brad S., Ranjana H. Advani, Neil E. Kay, et al.. (2005). Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood. 106(11). 4758–4758. 1 indexed citations
15.
Lin, Thomas S., Sabyasachi Biswas, Louie Naumovski, et al.. (2004). Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).. Blood. 104(11). 3486–3486. 2 indexed citations
16.
Mehta, Minesh P., Christina A. Meyers, Markus F. Renschler, et al.. (1999). 2082 Clinical trial of gadolinium texaphyrin (GD-TEX) in patients with brain metastases. International Journal of Radiation Oncology*Biology*Physics. 45(3). 320–320. 2 indexed citations
17.
Phan, See‐Chun, Brian T. Feeley, Donald A. Withers, & Linda M. Boxer. (1996). Identification of an Inducible Regulator of c- myb Expression during T-Cell Activation. Molecular and Cellular Biology. 16(5). 2387–2393. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anghel Adrian Udrea Breakdown of academic impact, for papers by Elisa Tassinari Breakdown of academic impact, for papers by C. Ligorio Breakdown of academic impact, for papers by B. Killing Breakdown of academic impact, for papers by Keiichi Akahoshi Breakdown of academic impact, for papers by Rita P. Dalal Breakdown of academic impact, for papers by Quanren Wang Breakdown of academic impact, for papers by Ayako Mizota Breakdown of academic impact, for papers by Minhao Fan
Rankless by CCL
2026